Page 137 - 《中国药房》2022年12期

inhibition disrupts rewired homologous recombination 478-488.
and fork protection pathways in PARP inhibitor-resistant [37] FERRI E，PETOSA C，MCKENNA C E. Bromodomains：
BRCA-deficient cancer cells[J]. Genes Dev，2017，31（3）： Structure，function and pharmacology of inhibition[J].
318-332. Biochem Pharmacol，2016，106：1-18.
[26] NING J F，STANCIU M，HUMPHREY M R，et al. Myc [38] MILLER A L，FEHLING S C，GARCIA P L，et al. The
targeted CDK18 promotes ATR and homologous recombi- BET inhibitor JQ1 attenuates double-strand break repair
nation to mediate PARP inhibitor resistance in glioblastoma and sensitizes models of pancreatic ductal adenocarcinoma
[J]. Nat Commun，2019，10（1）：2910. to PARP inhibitors[J]. EBioMedicine，2019，44：419-430.
[27] KIM H，XU H N，GEORGE E，et al. Combining PARP [39] PAWAR A，GOLLAVILLI P N，WANG S M，et al. Resis-
with ATR inhibition overcomes PARP inhibitor and plati- tance to BET inhibitor leads to alternative therapeutic vul-
num resistance in ovarian cancer models[J]. Nat Com- nerabilities in castration-resistant prostate cancer[J]. Cell
mun，2020，11（1）：3726. Rep，2019，29（5）：1397.
[28] SOUTHGATE H E D，CHEN L D，TWEDDLE D A，et al. [40] KARAKASHEV S，ZHU H R，YOKOYAMA Y，et al.
ATR inhibition potentiates PARP inhibitor cytotoxicity in BET bromodomain inhibition synergizes with PARP inhibitor
high risk neuroblastoma cell lines by multiple mecha- in epithelial ovarian cancer[J]. Cell Rep，2017，21（12）：
nisms[J]. Cancers（Basel），2020，12（5）：E1095. 3398-3405.
[29] BURGESS B T，ANDERSON A M，MCCORKLE J R， [41] 卞兴. PARP 抑制剂联合 BET 抑制剂靶向 MYC-PARP1
et al. Olaparib combined with an ATR or Chk1 inhibitor as 轴治疗小细胞肺癌的作用及潜在的分子机制研究[D].
a treatment strategy for acquired olaparib-resistant BRCA1 合肥：中国科学技术大学，2020.
mutant ovarian cells[J]. Diagnostics（Basel），2020，10（2）： [42] CHOU J，QUIGLEY D A，ROBINSON T M，et al. Tran-
E121. scription-associated cyclin-dependent kinases as targets
[30] JETTE N，RADHAMANI S，ARTHUR G，et al. P1.14-41 and biomarkers for cancer therapy[J]. Cancer Discov，
the combination of the PARP inhibitor olaparib and the 2020，10（3）：351-370.
ATR inhibitor VE-821 selectively targets ATM-deficient [43] JOHNSON S F，CRUZ C，GREIFENBERG A K，et al.
lung cancer cells[J]. J Thorac Oncol，2019，14（10）：S570- CDK12 inhibition reverses de novo and acquired PARP in-
S571. hibitor resistance in BRCA wild-type and mutated models
[31] GIUNTA E F，BELLI V，NAPOLITANO S，et al. 13P sy- of triple-negative breast cancer[J]. Cell Rep，2016，17（9）：
nergistic activity of PARP inhibitor and ATR inhibitor in 2367-2381.
melanoma cell lines may depend on BRAF-V600 muta- [44] JOSHI P M，SUTOR S L，HUNTOON C J，et al. Ovarian
tion status[J]. Ann Oncol，2020，31：S248-S249. cancer-associated mutations disable catalytic activity of
[32] SCHOONEN P M，KOK Y P，WIERENGA E，et al. Pre- CDK12，a kinase that promotes homologous recombina-
mature mitotic entry induced by ATR inhibition potentiates tion repair and resistance to cisplatin and poly（ADP-ri-
olaparib inhibition-mediated genomic instability，inflam- bose）polymerase inhibitors[J]. J Biol Chem，2014，289
matory signaling，and cytotoxicity in BRCA2-deficient （13）：9247-9253.
cancer cells[J]. Mol Oncol，2019，13（11）：2422- 2440. [45] SULLIVAN R J，FLAHERTY K T. Immunotherapy：
[33] KIM H，GEORGE E，RAGLAND R，et al. Targeting the anti-PD-1 therapies-a new first-line option in advanced
ATR/CHK1 axis with PARP inhibition results in tumor re- melanoma[J]. Nat Rev Clin Oncol. 2015，12（11）：625-
gression in BRCA-mutant ovarian cancer models[J]. Clin 626.
Cancer Res，2017，23（12）：3097-3108. [46] WANG Z B，SUN K M，XIAO Y H，et al. Niraparib acti-
[34] BRILL E，YOKOYAMA T，NAIR J，et al. Prexasertib，a vates interferon signaling and potentiates anti-PD-1 anti-
cell cycle checkpoint kinases 1 and 2 inhibitor，increases body efficacy in tumor models[J]. Sci Rep，2019，9（1）：
in vitro toxicity of PARP inhibition by preventing Rad51 1853.
foci formation in BRCA wild type high-grade serous ovarian [47] DING L Y，KIM H J，WANG Q W，et al. PARP inhibition
cancer[J]. Oncotarget，2017，8（67）：111026-111040. elicits STING-dependent antitumor immunity in Brca1-de-
[35] SMITH H L，PRENDERGAST L，CURTIN N J. Explo- ficient ovarian cancer[J]. Cell Rep，2018，25（11）：2972-
ring the synergy between PARP and CHK1 inhibition in 2980.e5.
matched BRCA2 mutant and corrected cells[J]. Cancers [48] WIEGMANS A P，YAP P Y，WARD A，et al. Differences
（Basel），2020，12（4）：E878. in expression of key DNA damage repair genes after epi-
[36] JIN J，FANG H H，YANG F，et al. Combined inhibition of genetic-induced BRCAness dictate synthetic lethality with
ATR and WEE1 as a novel therapeutic strategy in tri- PARP1 inhibition[J]. Mol Cancer Ther，2015，14（10）：
ple-negative breast cancer[J]. Neoplasia，2018，20（5）： 2321-2331.

中国药房 2022年第33卷第12期 China Pharmacy 2022 Vol. 33 No. 12 ·1535 ·